Top

Published in:

01-03-2017 | Reply

Author’s Reply to Proost: “Challenges in Individualizing Drug Dosage for Intensive Care Unit Patients”

Author: Roger W. Jelliffe

Published in: Clinical Pharmacokinetics | Issue 3/2017

Excerpt

I refer to the comments by Dr. Proost [1] on my paper published in Clinical Pharmacokinetics in August 2016 [2]. Dr. Proost says that I use an “incorrect approach” to pharmacokinetics, and that my conclusions “might have been different if I had used the correct approach.” He also makes many other assertions, several of which have significant clinical implications, so there is a lot to discuss, even after omitting several points. …

Proost JH. Comment on: "Challenges in individualizing drug dosage for intensive care unit patients". [letter]. Clin Pharmacokinet.

Jelliffe R. Challenges in individualizing drug dosage for intensive care unit patients: is augmented renal clearance what we really want to know? Some suggested management approaches and clinical software tools. Clin Pharmacokinet. 2016;55(8):897–905. doi:10.1007/s40262-016-0369-4.CrossRefPubMed

D’Argenio D. Optimal sampling times for pharmacokinetic experiments. J Pharmacokinet Biopharmacol. 1981;9:739–56.CrossRef

Bayard D, Jelliffe R, Neely M. Bayes risk as an alternative to fisher information in determining experimental designs for nonparametric models [slides and abstracts]. Population Optimal Design of Experiments Conference, Lilly Laboratories, Erl Wood Manor, Windesham, Surrey, UK, June 15, 2013. http://www.maths.qmul.ac.uk/~bb/PODE/PODE2013_Slides/PODE2013_RogerJelliffe.pdf. Accessed 8 Dec 2016.

Jelliffe R, Bayard D, Neely M. MMopt—an optimal TDM protocol strategy based on Bayes risk and weighted Bayes risk [oral presentation]. In: 14th congress of the international Association for Therapeutic Drug Monitoring and Clinical Toxicology, 14 Oct 2015, Rotterdam.

Bayard D, Jelliffe R. A Bayesian approach to tracking patients having changing pharmacokinetic parameters. J Pharmacokinet Pharmacodyn. 2004;31(1):75–107.CrossRefPubMed

Blom HAP. An efficient filter for abruptly changing systems [abstract]. In: 23rd IEEE conference on decision and control, 12–14 Dec 1984, Las Vegas.

Blom HAP, Bar-Shalom Y. The interacting multiple model algorithm for systems with Markovian switching coefficients. IEEE Trans Autom Control. 1988;33:780–3.CrossRef

Macdonald I, Staatz C, Jelliffe R, Thomson A. Evaluation and comparison of simple multiple model, richer data multiple model, and sequential interacting multiple model (IMM) Bayesian analyses of gentamicin and vancomycin data collected from patients undergoing cardiothoracic surgery. Ther Drug Monit. 2008;30:67–74.CrossRefPubMedPubMedCentral

10.

Jelliffe R. Estimation of creatinine clearance in patients with unstable renal function, without a urine specimen. Am J Nephrol. 2002;22:320–4.CrossRefPubMed

11.

Jelliffe R. Optimal methodology is important for optimal pharmacokinetic studies, therapeutic drug monitoring, and patient care [commentary]. Clin Pharmacokinet. 2015;54(9):887–92. doi:10.1007/s40262-015-0280-4.CrossRefPubMed

12.

Goodwin G, Payne R. Dynamic system identification: experiment design and data analysis. New York: Academic Press; 1977. p. 50 (Theorem 3.4.1).

13.

Rowland M, Benet L, Graham G. Clearance concepts in pharmacokinetics. J Pharmacokinet Biopharm. 1973;1(2):123–36.CrossRefPubMed

14.

Mehvar R. The relationship among pharmacokinetic parameters: effects of altered kinetics on the drug plasma concentration-time profiles. Am J Pharm Educ. 2004;68(2):1–9.

15.

Jelliffe R, Neely M, editors. Individualized drug therapy for patients: basic foundations, relevant software and clinical applications. 1st ed. Elsevier.

Title: Author’s Reply to Proost: “Challenges in Individualizing Drug Dosage for Intensive Care Unit Patients”
Author: Roger W. Jelliffe
Publication date: 01-03-2017
Publisher: Springer International Publishing
Published in: Clinical Pharmacokinetics / Issue 3/2017
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI: https://doi.org/10.1007/s40262-016-0482-4

At a glance: The STEP trials

Springer Medicine

Author’s Reply to Proost: “Challenges in Individualizing Drug Dosage for Intensive Care Unit Patients”

Excerpt

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2017

Clinical Pharmacokinetics and Pharmacodynamics of Afatinib

Development of a Pharmacokinetic Model to Describe the Complex Pharmacokinetics of Pazopanib in Cancer Patients

Prospective Analysis in GIST Patients on the Role of Alpha-1 Acid Glycoprotein in Imatinib Exposure

Allometric Scaling of Clearance in Paediatric Patients: When Does the Magic of 0.75 Fade?

A Strategy for Dosing Vancomycin to Therapeutic Targets Using Only Trough Concentrations

Clinical Pharmacokinetics and Pharmacodynamics of Safinamide